Holen Sie sich die Stockscreener-App
50.23
1.91%
0.94
Schlusskurs vom Vortag:
$49.29
Offen:
$48.48
24-Stunden-Volumen:
2.75M
Relative Volume:
1.12
Marktkapitalisierung:
$4.79B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-17.94
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
-4.38%
1M Leistung:
-30.54%
6M Leistung:
+35.79%
1J Leistung:
+8.51%
1-Tages-Spanne:
$48.02
$51.45
1-Wochen-Bereich:
$48.02
$55.77
52-Wochen-Spanne:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Vergleichen Sie CRSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
50.23 | 4.70B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Del Sette Capital Management LLC Buys New Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics AG Faces Stock Price Slide - TipRanks
Rockefeller Capital Management L.P. Purchases 24,853 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG $CRSP Shares Acquired by Geode Capital Management LLC - MarketBeat
CRISPR Therapeutics Hits Day High with 8.24% Surge in Stock Price - Markets Mojo
Can CRISPR Therapeutics AG stock deliver surprise earnings beatWeekly Risk Summary & Daily Oversold Bounce Ideas - newser.com
CRISPR Therapeutics Hits Day Low at $48.24 Amid Price Pressure - Markets Mojo
Is CRISPR Therapeutics AG (1CG) stock undervalued after correctionJuly 2025 Update & Fast Entry High Yield Tips - newser.com
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential - Finviz
How CRISPR Therapeutics AG stock performs after earningsLong Setup & Stepwise Entry and Exit Trade Signals - newser.com
How dovish Fed policy supports CRISPR Therapeutics AG (1CG) stock2025 Momentum Check & Safe Capital Growth Tips - newser.com
Is CRISPR Therapeutics AG (1CG) stock prepared for digital transition2025 Major Catalysts & High Conviction Trade Alerts - newser.com
SG Americas Securities LLC Acquires 9,141 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Is CRISPR Therapeutics AG (1CG) stock worth holding before Fed meetingTrend Reversal & Consistent Growth Stock Picks - newser.com
Alteri Wealth LLC Takes $269,000 Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Will CRISPR Therapeutics AG (1CG) stock keep high P E multiplesJuly 2025 Price Swings & Capital Efficient Trade Techniques - newser.com
Is CRISPR Therapeutics AG stock recession proof2025 AllTime Highs & Real-Time Chart Breakout Alerts - newser.com
Has CRISPR Therapeutics AG found a price floorQuarterly Market Summary & Risk Controlled Daily Trade Plans - newser.com
Why CRISPR Therapeutics AG (1CG) stock is listed among top recommendationsEarnings Recap Report & Verified Chart Pattern Trade Signals - newser.com
Is CRISPR Therapeutics AG (1CG) stock a buy on weaknessJuly 2025 Action & AI Enhanced Trading Alerts - newser.com
Vertex, Crispr’s Casgevy Accused of Infringing New ToolGen Patent - news.bloomberglaw.com
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First? - Barchart.com
How to build a dashboard for CRISPR Therapeutics AG stockEarnings Overview Summary & Expert Approved Momentum Ideas - newser.com
CRISPR Therapeutics stock pops following disclosure of RFK Jr. investment - MSN
Is CRISPR Therapeutics AG showing signs of accumulationJuly 2025 Fed Impact & Smart Money Movement Tracker - newser.com
What to do if you’re stuck in CRISPR Therapeutics AGWeekly Trade Analysis & Proven Capital Preservation Tips - newser.com
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. - The Motley Fool
Reversal indicators forming on CRISPR Therapeutics AG stock2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
Published on: 2025-11-18 23:19:07 - newser.com
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):